Identifying What to Measure in Acne Clinical Trials: First Steps towards Development of a Core Outcome Set  Alison M. Layton, E. Anne Eady, Diane M. Thiboutot, Jerry Tan Flordeliz Abad-Casintahan, Ketaki Bhate, Fiona Collier, Fiona Cowdell, Claudia Donkor, Leon Kircik, Megan Landis, Shari Marchbein, Sandra Nijland, Falk Ochsendorf, Nanette Silverberg, Guy Webster, Jonathan Weiss Alison M. Layton, E. Anne Eady, Diane M. Thiboutot, Jerry Tan Flordeliz Abad-Casintahan, Ketaki Bhate, Fiona Collier, Fiona Cowdell, Claudia Donkor, Leon Kircik, Megan Landis, Shari Marchbein, Sandra Nijland, Falk Ochsendorf, Nanette Silverberg, Guy Webster, Jonathan Weiss  Journal of Investigative Dermatology  Volume 137, Issue 8, Pages 1784-1786 (August 2017) DOI: 10.1016/j.jid.2017.04.017 Copyright © 2017 The Authors Terms and Conditions

Figure 1 International participation in defining core outcome domains in acne clinical trials. (a) Demographics of the 500 participants in round 1 (respondent type adds up to >500 as some participants selected more than one option). (b) Demographics of the 116 participants in round 3. There were 164 participants in round 2: 112 professionals (including 9 editors and 10 industry personnel) and 52 patients (data not shown). (c) Responses to ranking importance of the initial 24 items in round 1. The top 12 items are shown in black. Two items in red were taken forward into round 2 after consultation with the Outcomes Identification Group. (d) Seven core outcome domains were identified after all three rounds had been completed. Domains in gray and green were decided by consensus in rounds 2 and 3, respectively. Adverse events (in red) was chosen before the exercise based on recommendations in the literature (see text). HCP, health care practitioner. Journal of Investigative Dermatology 2017 137, 1784-1786DOI: (10.1016/j.jid.2017.04.017) Copyright © 2017 The Authors Terms and Conditions